Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops anti-infective agents for the treatment of infections. The company offers product candidates such as Xenleta (lefamulin), and CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia. Its other pipeline products comprise BC-7013 for the topical treatment of a variety of gram-positive infections including uncomplicated skin and skin structure infections and Contepo to treat urinary tract infections. It partners with pharmaceutical and biotechnology companies. It has an operational presence in Austria, Ireland and the US. Nabriva is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
Alexandra House Office 225/227, , The Sweepstakes, Ballsbridge, Dublin, D01H104
Website
www.nabriva.com
Telephone
353 61 08166640
No of Employees
39
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NBRVF (OTC)
Revenue (2021)
$36.9M
27.8%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-15.6%
(2021 vs 2020)
Net Profit Margin (2021)
XYZ
9.5%
(2021 vs 2020)
* As of and is in US$
Nabriva Therapeutics Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Lefamulin |
| Contepo |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Nabriva Therapeutics Plc | ICON Plc | Alkermes Plc | AstraZeneca Pharmaceuticals (Ireland) Ltd |
|---|---|---|---|---|
| Headquarters | Ireland | Ireland | Ireland | Ireland |
| City | Dublin | Dublin | Dublin | Dublin City |
| State/Province | - | Dublin | - | Dublin |
| No. of Employees | 39 | 41,100 | 2,100 | - |
| Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel Burgess | Chairman | Executive Board | 2017 | 61 |
| Daniel Dolan | Chief Financial Officer | Senior Management | 2021 | 46 |
| Christopher Naftzger | Chief Executive Officer - Interim; General Counsel; Secretary | Senior Management | 2021 | 55 |
| Steven Gelone | Director | Non Executive Board | 2021 | 55 |
| Colin Broom | Director | Non Executive Board | 2017 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer